• DOI:10.1191/1352458502ms776oa
Corpus ID: 45994154

Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination

@article{Moscarello2002PaclitaxelA,
  title={Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination},
  author={M. Moscarello and B. Mak and T. A. Nguyễn and D. Wood and F. Mastronardi and S. Ludwin},
  journal={Multiple Sclerosis},
  year={2002},
  volume={8},
  pages={130 - 138}
}

M. Moscarello, B. Mak, +3 authors S. Ludwin

Published 2002

Medicine

Multiple Sclerosis

Treatment with paclitaxel by four intraperitoneal injections (20 mg/kg) 1 week apart attenuated clinical signs in a spontaneously demyelinating model, if given with onset of clinical signs. If given at 2 months of age (1 month prior to clinical signs), disease was almost completely prevented. The astrogliosis, prominent in our model, was reversed by paclitaxel as determined by astrocyte counts and quantitation of GFAP. Electron microscopic examination of affected regions at 2.5 months… CONTINUE READING

View on SAGE

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed